What question did this study set out to answer?

Evaluate the safety and effectiveness of cangrelor as a rescue therapy for acute thrombosis during neuroendovascular procedures.

April 10, 2026Open Access

Intravenous cangrelor as rescue therapy for acute thrombosis in neuroendovascular procedures: illustrative cases

Key Result

Intravenous cangrelor served as a safe and effective rescue therapy with emergency thrombolysis capability for acute thrombosis following cerebral aneurysm embolization.

Key Points

Evaluate the safety and effectiveness of cangrelor as a rescue therapy for acute thrombosis during neuroendovascular procedures.
Administered intravenous cangrelor in cases of acute thrombosis
Monitored for thrombolysis effectiveness after cerebral aneurysm embolization
Assessed safety and rapid onset effects of cangrelor
Cangrelor effectively achieved emergency thrombolysis in patients
Demonstrated rapid onset of action with reversible P2Y12 inhibition
Showed an extremely short half-life, allowing for quick management changes

Structured PICO

Does intravenous cangrelor act as a safe and effective rescue therapy for acute thrombosis during neuroendovascular procedures?

Population

Patients experiencing acute thrombosis after cerebral aneurysm embolization (limited case series)

Intervention

Intravenous cangrelor as rescue therapy

Outcome

Safety and efficacy (emergency thrombolysis capability)

Intravenous cangrelor may serve as an attractive rescue agent for acute thrombosis during neuroendovascular procedures due to its rapid onset, reversible inhibition, and short half-life.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

In this limited series, cangrelor was found to be a safe and effective IV platelet inhibitor with emergency thrombolysis capability after cerebral aneurysm embolization. Cangrelor is an attractive rescue agent due to its rapid onset, reversible P2Y12 inhibition, and extremely short half-life (on/off effect). https://thejns.org/doi/10.3171/CASE25930.